Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 9, 2020
Reporting Period: This filing announces financial results for the year and quarter ended December 31, 2019. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover report referencing a press release (Exhibit 99.1) for the actual financial data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific numerical metrics.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It serves solely to notify the market of the issuance of the 2019 annual and quarterly results.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing management's discussion of the 2019 results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 9, 2020) for specific revenue, net loss, and cash position figures.
- Verify the company's liquidity status and runway given the biopharma sector context.
- Check for any forward-looking statements or updated clinical trial timelines in the referenced press release.
- Confirm the trading symbol (MTNB) on the NYSE American exchange.